-
Pfizer shuts down development of PCSK9 inhibitor
NEW YORK — Pfizer has discontinued the global clinical development program around its investigational high cholesterol treatment bococizumab, the company announced Tuesday, noting that because of information available about the treatment and the current market landscape, it wasn’t likely to create value for patients, doctors or shareholders.